ReviewVeterinary medicine and science2025
Reapplication of the Type IV Hypersensitivity Quantitative Risk Assessment to Assess Ingredients Used on Canines.
Review in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A quantitative risk assessment (QRA) framework to assess the risk for the induction of human skin sensitization from exposure to contact allergens has been successfully developed and applied. So far, the QRA has not been applied in a canine risk assessment for establishing concentration limits of ingredients with Type IV hypersensitivity potential. Outlining this risk assessment is critical, as shampoos are known to cause allergic contact dermatitis (ACD) in canines. Additionally, humans have developed ACD after washing their dogs with dog shampoo. To address this gap, we conducted a thorough literature review on canine Type IV hypersensitivity and identified potential differences which might demand an adaptation of the QRA. We summarize data from the literature demonstrating that all four key events (KE) in the skin sensitization adverse outcome pathway (AOP) are present in dogs as they are in humans, guinea pigs, and mice. The hazard potential of sensitizers for canines is compared with the established sensitization QRA framework for humans. The limited collective evidence suggests that dogs are not more susceptible to sensitizers than humans; therefore, safety-defined concentration limits from Type IV hypersensitivity risk assessments for humans can be re-applied to canines so long as their unique exposure considerations are factored in. Using the principles in this review, one can evaluate chemical sensitizers to support the safe development of new topical formulations for canines. The result of applying our current best approaches for assessing ACD to canine products should protect both the pet and the owners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.